Prescient Therapeutics Limited

ASX:PTX Stock Report

Market Cap: AU$33.0m

Prescient Therapeutics Management

Management criteria checks 3/4

Prescient Therapeutics' CEO is Steven Yatomi-Clarke, appointed in Feb 2016, has a tenure of 8.83 years. total yearly compensation is A$657.01K, comprised of 63% salary and 37% bonuses, including company stock and options. directly owns 1.39% of the company’s shares, worth A$458.99K. The average tenure of the management team and the board of directors is 9.3 years and 9.6 years respectively.

Key information

Steven Yatomi-Clarke

Chief executive officer

AU$657.0k

Total compensation

CEO salary percentage63.0%
CEO tenure8.8yrs
CEO ownership1.4%
Management average tenure9.3yrs
Board average tenure9.6yrs

Recent management updates

Recent updates

Here's Why We're Not Too Worried About Prescient Therapeutics' (ASX:PTX) Cash Burn Situation

Jul 05
Here's Why We're Not Too Worried About Prescient Therapeutics' (ASX:PTX) Cash Burn Situation

We Think Prescient Therapeutics (ASX:PTX) Can Afford To Drive Business Growth

Mar 12
We Think Prescient Therapeutics (ASX:PTX) Can Afford To Drive Business Growth

We're Not Very Worried About Prescient Therapeutics' (ASX:PTX) Cash Burn Rate

Nov 14
We're Not Very Worried About Prescient Therapeutics' (ASX:PTX) Cash Burn Rate

Companies Like Prescient Therapeutics (ASX:PTX) Are In A Position To Invest In Growth

Aug 01
Companies Like Prescient Therapeutics (ASX:PTX) Are In A Position To Invest In Growth

Shareholders Would Not Be Objecting To Prescient Therapeutics Limited's (ASX:PTX) CEO Compensation And Here's Why

Nov 22
Shareholders Would Not Be Objecting To Prescient Therapeutics Limited's (ASX:PTX) CEO Compensation And Here's Why

Here's Why We're Not Too Worried About Prescient Therapeutics' (ASX:PTX) Cash Burn Situation

Oct 19
Here's Why We're Not Too Worried About Prescient Therapeutics' (ASX:PTX) Cash Burn Situation

Prescient Therapeutics (ASX:PTX) Is In A Strong Position To Grow Its Business

Jun 19
Prescient Therapeutics (ASX:PTX) Is In A Strong Position To Grow Its Business

Prescient Therapeutics (ASX:PTX) Is In A Strong Position To Grow Its Business

Feb 27
Prescient Therapeutics (ASX:PTX) Is In A Strong Position To Grow Its Business

We Think Shareholders Are Less Likely To Approve A Large Pay Rise For Prescient Therapeutics Limited's (ASX:PTX) CEO For Now

Nov 05
We Think Shareholders Are Less Likely To Approve A Large Pay Rise For Prescient Therapeutics Limited's (ASX:PTX) CEO For Now

We Think Prescient Therapeutics (ASX:PTX) Can Easily Afford To Drive Business Growth

Aug 26
We Think Prescient Therapeutics (ASX:PTX) Can Easily Afford To Drive Business Growth

Prescient Therapeutics (ASX:PTX) Is In A Good Position To Deliver On Growth Plans

May 08
Prescient Therapeutics (ASX:PTX) Is In A Good Position To Deliver On Growth Plans

Does Prescient Therapeutics' (ASX:PTX) CEO Salary Compare Well With The Performance Of The Company?

Jan 11
Does Prescient Therapeutics' (ASX:PTX) CEO Salary Compare Well With The Performance Of The Company?

CEO Compensation Analysis

How has Steven Yatomi-Clarke's remuneration changed compared to Prescient Therapeutics's earnings?
DateTotal CompensationSalaryCompany Earnings
Jun 30 2024AU$657kAU$414k

-AU$8m

Mar 31 2024n/an/a

-AU$8m

Dec 31 2023n/an/a

-AU$8m

Sep 30 2023n/an/a

-AU$7m

Jun 30 2023AU$663kAU$400k

-AU$7m

Mar 31 2023n/an/a

-AU$6m

Dec 31 2022n/an/a

-AU$5m

Sep 30 2022n/an/a

-AU$5m

Jun 30 2022AU$771kAU$392k

-AU$5m

Mar 31 2022n/an/a

-AU$5m

Dec 31 2021n/an/a

-AU$5m

Sep 30 2021n/an/a

-AU$5m

Jun 30 2021AU$800kAU$360k

-AU$4m

Mar 31 2021n/an/a

-AU$4m

Dec 31 2020n/an/a

-AU$3m

Sep 30 2020n/an/a

-AU$3m

Jun 30 2020AU$639kAU$392k

-AU$3m

Mar 31 2020n/an/a

-AU$4m

Dec 31 2019n/an/a

-AU$4m

Sep 30 2019n/an/a

-AU$4m

Jun 30 2019AU$586kAU$367k

-AU$4m

Mar 31 2019n/an/a

-AU$3m

Dec 31 2018n/an/a

-AU$3m

Sep 30 2018n/an/a

-AU$3m

Jun 30 2018AU$479kAU$330k

-AU$3m

Compensation vs Market: Steven's total compensation ($USD410.91K) is above average for companies of similar size in the Australian market ($USD291.23K).

Compensation vs Earnings: Steven's compensation has been consistent with company performance over the past year.

CEO

Steven Yatomi-Clarke

8.8yrs

Tenure

AU$657,007

Compensation

Mr. Steven Lee Yatomi-Clarke has been Chief Executive Officer and Managing Director of Prescient Therapeutics Limited since February 15, 2016. Mr. Yatomi-Clarke has been Director of Prescient Therapeutics...

Leadership Team

NamePositionTenureCompensationOwnership
Steven Yatomi-Clarke
MD, CEO & Director8.8yrsAU$657.01k1.39%
A$ 459.0k
Melanie Leydin
CFO & Company Secretary9.8yrsAU$158.40kno data
Upaly Bahadure
Director of Clinical Affairs & Operationsless than a yearno datano data
Terrence Chew
Chief Medical Officer9.7yrsAU$157.36kno data

9.3yrs

Average Tenure

Experienced Management: PTX's management team is seasoned and experienced (9.3 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Steven Yatomi-Clarke
MD, CEO & Director10.1yrsAU$657.01k1.39%
A$ 459.0k
Steven Engle
Independent Non-Executive Chairman10.5yrsAU$97.96k0.027%
A$ 9.0k
James Campbell
Independent Non-Executive Director10.1yrsAU$61.41k0.049%
A$ 16.3k
Rodney Sinclair
Chairman of Clinical Advisory Board13.5yrsno datano data
Reinhard Dummer
Member of Clinical Advisory Board13.5yrsno datano data
Joshua Douglas
Member of Scientific Advisory Board10.3yrsno datano data
Farhad Ravandi
Member of Scientific Advisory Board9.1yrsno datano data
Jeffrey Lancet
Member of Scientific Advisory Board9.1yrsno datano data
H. Prince
Member of Scientific Advisory Board4yrsno datano data
Thomas Prebet
Member of Scientific Advisory Board8.9yrsno datano data
Allen Ebens
Non-Executive Director4.5yrsAU$61.41kno data
Phillip Darcy
Member of Scientific Advisory Board4.3yrsno datano data

9.6yrs

Average Tenure

Experienced Board: PTX's board of directors are considered experienced (9.6 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/23 06:27
End of Day Share Price 2024/12/23 00:00
Earnings2024/06/30
Annual Earnings2024/06/30

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Prescient Therapeutics Limited is covered by 2 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Paul HickmanEdison Investment Research
Joseph PantginisH.C. Wainwright & Co.